Anixa Biosciences, Inc.
ANIXAnixa Biosciences, Inc. is a biotechnology company focused on the development of cancer immunotherapies and infectious disease vaccines. The company leverages its immuno-oncology platform to create targeted treatments aimed at improving patient outcomes, with a particular emphasis on cancer vaccines and therapies.
Company News
Anixa Biosciences announced that the Mexican Institute of Industrial Property has issued Patent Number 432748 covering the company's breast cancer vaccine technology. The patent extends intellectual property protection into 2040 and strengthens Anixa's global patent portfolio. The vaccine, developed with Cleveland Clinic, targets human α-lactalb...
Anixa Biosciences announced that South Korea's Ministry of Intellectual Property issued a Notice of Allowance for a patent covering the company's breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition of matter protection in South Korea and expands Anixa's global intellectual property portfo...
The cancer immunotherapy market is projected to reach $258.22 billion by 2031, driven by breakthrough treatments and FDA fast-track approvals. Multiple companies are developing innovative immunotherapies targeting various cancer types with promising clinical trial results.
Anixa Biosciences, a biotechnology company focused on cancer treatment and prevention, will present at the Sidoti Micro-Cap Virtual Conference on November 13-14, 2024. The company will provide updates on its breast cancer and ovarian cancer clinical trials, which have been producing positive results.
The FDA has approved Anixa Biosciences' application for an individual patient trial of its CAR-T therapy for recurrent ovarian cancer patients who have failed standard-of-care treatments. The therapy has shown promising early results, with one patient demonstrating a notable response despite initial tumor progression.
